MONTE ROSA THERAPEUTICS INC
NASDAQ: GLUE (Monte Rosa Therapeutics, Inc.)
Last update: 2 hours ago10.76
-0.11 (-1.01%)
| Previous Close | 10.87 |
| Volume | 1,348,181 |
| Price / Sales | 34.99 |
| Price / Book | 1.90 |
| 52 Weeks Range |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Monte Rosa Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.2 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.01 |
Select this tab to load the latest available analysis.
|
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2026 | 7,692,298 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 4,622,151 |
| Montanova Capital, Llc | 30 Jun 2026 | 3,549,539 |
| Versant Venture Management, Llc | 30 Jun 2026 | 3,180,780 |
| Braidwell Lp | 30 Jun 2026 | 2,451,562 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |